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576Objective: The objective of this study was to evaluate whether remote ischemic preconditioning can protect
kidney function in children undergoing operation for complex congenital heart disease.
Methods: Children (n ¼ 113) aged 0 to 15 years admitted for complex congenital heart disease were randomly
allocated according to age to remote ischemic preconditioning and control groups. After exclusion of 8 patients,
we conducted the analysis on 105 patients (remote ischemic preconditioning group, n ¼ 54; control group,
n ¼ 51). Before surgery, remote ischemic preconditioning was performed as 4 cycles of 5 minutes of ischemia
by inflating a cuff around a leg to 40 mm Hg above the systolic pressure. End points were development of acute
kidney injury, initiation of dialysis, plasma creatinine, estimated glomerular filtration rate, plasma cystatin C,
plasma and urinary neutrophil gelatinase–associated lipocalin, and urinary output. Secondary end points in-
cluded postoperative blood pressure, inotropic score, and mortality, as well as morbidity reflected by reoperation
and stays in the intensive care unit and hospital.
Results: Overall, 57 of the children (54%) had acute kidney injury develop, with 27 (50%) in the remote ische-
mic preconditioning group and 30 (59%) in the control group (P>.2). Remote ischemic preconditioning was not
associated with improvement in either any of the renal biomarkers or any of the secondary end points.
Conclusions: We found no evidence that remote ischemic preconditioning provided protection of kidney
function in children undergoing operation for complex congenital heart disease. (J Thorac Cardiovasc Surg
2012;143:576-83)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Cardiovascular Surgand demonstrated that AKI independently almost doubled
the risk of death.1,2 The pathogenesis of AKI is thought
to lie in the initiation of a complex cascade of meta-
bolic consequences in the tubule cells caused by renal
ischemia–reperfusion injury, as well as development of an
inflammatory systemic response during surgery.3
Ischemic preconditioning refers to the intervention of in-
ducing mild ischemia in an organ that subsequently will be
subjected to prolonged ischemia.4 Ischemic preconditioning
activates endogenous protective mechanisms that amelio-
rate ischemia–reperfusion injury caused by the prolonged
ischemic episode. Remote ischemic preconditioning
(RIPC) refers to the intervention of inducing mild ischemia
in a tissue distant from the organ that later on will be at risk
for ischemia–reperfusion injury.5 RIPC can be performed as
short cycles of ischemia and reperfusion with an inflatable
cuff on a limb. RIPC has primarily been demonstrated to
protect the heart in adults and children undergoing cardiac
surgery,6-8 and ischemic preconditioning has proved
beneficial in several organs (liver, lung, and brain) in
human beings.9-11 Studies of the effect of RIPC on kidney
function in adults undergoing cardiovascular surgery have
shown conflicting results.12-16 The effect of RIPC onery c March 2012
Abbreviations and Acronyms
AKI ¼ acute kidney injury
CV ¼ coefficient of variation
ECC ¼ extracorporeal circulation
ICU ¼ intensive care unit
IS ¼ inotropic score
NGAL ¼ neutrophil gelatinase–associated
lipocalin
POD ¼ postoperative day
RACHS-1 ¼ Risk Adjustment for Congenital
Heart Surgery 1
RIPC ¼ remote ischemic preconditioning
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Dkidney function in children undergoing operation for
congenital heart disease has not yet been investigated. The
specific objective of this study was to test the effect of
RIPC on kidney function in children undergoing operation
for congenital heart disease. The hypothesis was that
RIPC would decrease the incidence of postoperative AKI.MATERIALS AND METHODS
Study Population
Power calculation performed before the study resulted in a study popu-
lation of 90 children, with 45 patients in each group. The calculation was
based on the assumption that 50% of all children would have at least
a 50% increase in plasma creatinine postoperatively and that RIPC would
reduce this frequency to 20% (power 0.8 and a 5% significance level).
The trial inclusion was stopped when 113 children had been randomly
allocated.
This was a single center, stratified (0–1 month,>1 month–2 years,>2–5
years, and>5–15 years, with balanced randomization 1:1), double-blind,
controlled, parallel-group study. Children aged 0 to 15 years admitted for
surgery for congenital heart disease between July 2008 and December
2010 at Arhus University Hospital, Skejby, Denmark, were considered
for random allocation. We excluded operations of low complexity, such
as closure of septal defects and aorticopulmonary windows, establishment
of Glenn shunts, subaortic membrane resection, redirection of partial
anomalous pulmonary veins, valvotomies, repair of pulmonary artery ste-
nosis, and operations without the use of extracorporeal circulation (ECC),
with the purpose intent of achieving a study population with a relatively
high risk of AKI.
During the study period, 288 candidates were admitted for surgery,
among whom 150 met the inclusion criteria (Figure 1). Two patients
were included twice (>1 month between procedures with discharge in
between); 1 patient was randomly allocated to the RIPC group and
then the control group, and 1 patient was randomly allocated to the con-
trol group at both admissions. Before randomization, 37 patients were
excluded (lack of informed consent, n ¼ 7; operations required within
a few days, during which the consent for participation could not be ob-
tained because of logistics, n ¼ 21; and unavailability of study nurse,
n ¼ 9), and 113 patients were randomly allocated. After randomization,
we had to exclude 8 patients: 3 patients because of postoperative need
for extracorporeal membrane oxygenation (randomly allocated to the
RIPC group, n ¼ 2, and control group, n ¼ 1) and 5 patients who actu-
ally turned out to fulfill exclusion criteria (4 patients because of lack of
use of ECC, randomly allocated to the RIPC group, n ¼ 3, and controlThe Journal of Thoracic and Cagroup, n ¼ 1; 1 patient, with expected surgery for total anomalous pul-
monary veins, who only had surgery for partial anomalous pulmonary
veins, randomly allocated to the control group). Thus 105 patients
were left for analysis, with 54 in the RIPC group and 51 in the control
group (Figure 1).
The study was approved by the regional ethical committee, and in-
formed consent was procured. A computerized randomization table for
the random allocation of patients was established. A secretary blinded to
the randomization table assessed patient eligibility, and a study nurse,
not involved in analyzing data, enrolled patients and assigned and per-
formed the intervention. The cardiac surgeon and all care providers were
blinded to treatment.
Remote Ischemic Preconditioning
In the intervention group, RIPC was performed by applying a blood
pressure cuff (age-adjusted size) around the child’s leg. The cuff was in-
flated to 40 mm Hg above the systolic pressure in 4 cycles of 5 minutes.
Every cycle of ischemiawas followed by 5minutes of reperfusion. The first
RIPC cycle started after anesthesia induction, when invasive arterial blood
pressure monitoring was established. For reproducibility, RIPC was per-
formed on the right leg with only a few exceptions, when that leg was
used for invasive catheters. Time from the last RIPC cycle to initiation
and weaning of ECC was recorded. An uninflated cuff was applied on
the leg in the control group.
Patient Characteristics
We recorded the following patient characteristics in the 2 groups to
check for potential confounders after randomization: demographic data,
preoperative plasma creatinine (in micromoles per liter), estimated glomer-
ular filtration rate (eGFR) calculated with the Schwartz formula (eGFR [in
milliliters per minute per 1.73m2]¼ [k3 height]/[plasma creatinine/88.4],
where k¼ 0.45 in term infants up to 1 year old [all children were mature at
the date of surgery], k¼ 0.55 in children 1–13 years old, k¼ 0.65 in boys at
least 13 years old, and k ¼ 0.55 in girls at least 13 years old), preoperative
renal insufficiency (incidence of plasma creatinine above the reference
level corrected for age), the Risk Adjustment for Congenital Heart Surgery
1 (RACHS-1) score corresponding to each surgical procedure (score sys-
tem 1–6, with the highest number indicating the highest complexity of pro-
cedure17), preoperative hemoglobin, preoperative saturation, ECC time,
circulatory arrest, nadir temperature at ECC, incidence of univentricular
heart, incidence of chromosome abnormality and syndromes, and inci-
dence of previous heart surgery (1 surgical intervention). We also re-
corded the incidence of infections (defined as a combination of clinical
suspicion and use of antibiotics preoperatively or extended treatment
with antibiotics beyond the normal prophylactic treatment given for 48
hours or change from prophylactic cefuroxime to piperacillin sodium
[INN piperacillin] and tazobactam), because infection has been shown to
increase plasma neutrophil gelatinase–associated lipocalin (NGAL) inde-
pendently of AKI.18
The anesthetic drug regimen used was also registered (high-dose fen-
tanyl, sevoflurane and fentanyl/propofol, or propofol and fentanyl), be-
cause several investigations have shown a preconditioning-like effect of
volatile anesthetics.19
Renal End Points
Renal end points foremost included AKI (defined as fulfilling 1 of the
RIFLE criteria20: R, risk, plasma creatinine times 1.5 or urinary output
<0.5 mL/[kg $h] for 6 hours; I, injury, plasma creatinine times 2 or urinary
output<0.5 mL/[kg $ h] for 12 hours; F, failure, plasma creatinine times 3
or plasma creatinine 350 mmoL/L in the setting of an acute increase of at
least 44 mmoL/L or urinary output<0.3 mL/[kg $ h] for 24 hours or anuria
for 12 hours; L, loss, need for dialysis for longer than 4 weeks;E, end-stage,
need for dialysis for longer than 3 months), with patients categorizedrdiovascular Surgery c Volume 143, Number 3 577
FIGURE 1. Diagram of trial recruitment. ECC, Extracorporeal circulation.
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nine or urinary output. Initiation of dialysis (treatment with peritoneal di-
alysis or hemodialysis initiated on the basis of fluid overload, metabolic
acidosis, or hyperkalemia) was recorded. Plasma creatinine, eGFR, plasma
cystatin C, plasma NGAL, urinary NGAL, ratio of urinary NGAL to uri-
nary creatinine, and urinary output were also recorded.
Creatinine levels were analyzed by dry-slide technology with the Vitros
5.1 system (Ortho-Clinical Diagnostics, Inc, Rochester, NY) for routine
measurement.
Cystatin C levels were measured with the N Latex cystatin C assay on
the Behring Nephelometer II (Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany). The samples were analyzed in duplicate,
and all samples from each subject were analyzed in a single run. One tech-
nician performed all assays. The intra-assay coefficient of variation (CV)
was 2.5%, and the interassay CV was 4.9%.
NGAL levels were measured in duplicatewith a commercially available
enzyme-linked immunosorbent assay kit (kit 036; BioPorto Diagnostics
A/S, Gentofte, Denmark). The analyses were carried out as described in
our previous study, in which we validated the NGAL enzyme-linked immu-
nosorbent assay kit.21 For plasma, the intra-assay CV was 1.7%, and the
interassay CV was 8.1%. For urine, the intra-assay CV was 1.9%, and
the interassay CV was 10.5%. Macroscopic hemolysis in plasma and he-
maturia were registered. Urinary NGAL was divided by urinary creatinine
to correct for urine dilution.Secondary End Points
Secondary end points were as follows: low blood pressure (incidence of
postoperative arterial blood pressure below the age reference level), highest578 The Journal of Thoracic and Cardiovascular Surginotropic score (defined according to the inotropic score [IS] in which the
highest postoperative dose [in micrograms per kilogram per minute] was
used in the formula IS ¼ [(dopamine þ dobutamine) 3 1] þ
(milrinone 3 10)þ [(epinephrineþ norepinephrine) 3 100] to calculate
the IS22), reoperation during hospital stay, stay in the intensive care unit
(ICU), hospital stay (days from postoperative ICU arrival until discharge),
and in-hospital death.
Preoperative plasma and urine samples were collected after the induc-
tion of anesthesia, except for plasma creatinine which was taken within 1
week before surgery. Postoperative samples were collected at ICU arrival,
4 hours after ICU arrival, and in the mornings on postoperative day (POD)
1, POD 2, and POD 3. Sample collection stopped before POD 3 if the in-
vasive or bladder catheter was removed. The time point of collection was
registered for more than 70% of samples, and we found no difference be-
tween the RIPC and the control groups (mean  SD time in hours from
ECC end to sample collection at any of the prespecified time points) as fol-
lows: arrival at ICU, RIPC¼ 2.2 1.2 versus control¼ 2.3 1.1 (P>.2);
4 hours after ICU arrival, RIPC¼ 6.1 1.9 versus control¼ 5.8 1.6 (P>
.2); POD 1, RIPC ¼ 19  1.8 versus control ¼ 19  1.4 (P>.2); POD 2,
RIPC¼ 44 2.3 versus control¼ 44 2.5 (P>.2); POD 3, RIPC¼ 68
2.6 versus control ¼ 68  1.8 (P>.2).
All samples were centrifuged at 3500 rpm for 10 minutes, and the super-
natants were stored at80C until analysis. Data on urinary output, blood
pressure, and IS (averaged hourly from arrival at ICU until POD 3) were ob-
tained from the patient data management system (Picis Care Suite; Picis, Inc,
Wakefield,Mass) at the ICUandwere registered for thefirst postoperative day
(from ICU arrival to 6:00 AM on POD1) and for PODs 1 through 3 (6:00 AM–
6:00 AM). Data on reoperation during hospital stay, stay at the ICU, hospital
stay, and in-hospital deaths were obtained from the medical records.ery c March 2012
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Data are displayed as mean SD or asmedian and interquartile range as
appropriate. We used the Student t test or Mann-Whitney rank sum test as
appropriate to compare continuous variables and the c2 test or Fisher’s Ex-
act test to compare categoric variables. For measurements of every renal
biomarker, eGFR, urinary output, preoperative hemoglobin, and ECC
time, we transformed data to a logarithmic scale to fulfill the assumption
about normality.
For every renal biomarker, eGFR, and urinary output, we used multivar-
iate analyses of variance for repeated measurements to test for difference
across time points between the RIPC and control group. The hypothesis
of parallel curves was first tested with a likelihood ratio test; if this hypoth-
esis could not be rejected, the hypothesis of equal curves was tested. If the
hypothesis of equal curves could not be rejected, the hypothesis of differ-
ences between time points for the approximated common curve was tested.
STATA/IC 11.1 was used for data analysis.
Recruitment rate was lower than anticipated, but no changes to methods
had to be undertaken during the study. Funding agencies had no role inTABLE 1. Patient characteristics
N
Age (y, median and IQR) 1.
Age group (no.)
0–1 mo 1
>1 mo–2 y 1
>2–5 y 1
>5–15 y 1
Body surface area (m2, median and IQR) 0.
Sex (no.)
Girls 2
Boys 2
Preoperative plasma creatinine (mmoL/L, median and IQR) 3
Preoperative estimated glomerular filtration rate*
(mL/[min $ 1.73 m2], median and IQR)
11
Preoperative renal insufficiency (no.) 1
Risk Adjustment for Congenital Heart Surgery 1 score (no.)
2
3 3
4
6
Preoperative hemoglobin (g/dL, median and IQR) 11.
Preoperative saturation (%, median and IQR) 99%
ECC time (min, median and IQR) 13
Circulatory arrest time (min, median and IQR) 3
Nadir temperature at ECC (C, median and IQR) 2
Infection (no.)
Univentricular heart (no.)
Chromosome abnormality or syndrome (no.)
Anesthetic drug (no.)
High-dose fentanyl
Sevoflurane and fentanyl/propofol 4
Propofol and fentanyl
Previous heart surgery (no.) 2
RIPC on left rather than right leg (no.)
Time between RIPC and ECC start (min, median and IQR)x 6
Time between RIPC and ECC stop (min, median and IQR)x 18
RIPC, Remote ischemic preconditioning; IQR, interquartile range; ECC, extracorporeal cir
(k3 height)/(plasma creatinine/88.4), where k is 0.45 in term infants up to 1 year old, k is 0
girls at least 13 years old. Preoperative renal insufficiency defined as incidence of plasma
The Journal of Thoracic and Cadesigning the study, interpreting the data, writing the report, or making
the decision to submit the report for publication.RESULTS
Patient characteristics were similar in the RIPC group
and the control group (Table 1). No unintended effects or
harm of RIPC were detected.Renal End Points
In the RIPC group, 27 (50%) had AKI develop, com-
pared with 30 (59%) in the control group (P> .2; Table
2), which was also the result for the incidence of at least
a 50% increase in plasma creatinine. AKI was diagnosed
on the basis of an isolated creatinine increase in 81% of
the children, whereas in 19% it was diagnosed on the basisRIPC Control P value
54 51
0 (0.2–6.0) 0.9 (0.2–5.0) .68
.98
1 (20%) 12 (24%)
8 (33%) 16 (31%)
0 (19%) 10 (20%)
5 (28%) 13 (26%)
4 (0.3–0.9) 0.4 (0.2–0.7) .81
.06
9 (54%) 18 (35%)
5 (46%) 33 (65%)
5 (27–48) 32 (26–48) .48
5 (68–152) 114 (67–158) .93
6 (30%) 16 (31%) .85
6 (11%) 8 (16%)
8 (70%) 35 (69%)
9 (17%) 8 (16%)
1 (2%) 0 (0%)
8 (10.3–13.1) 10.8 (10.0–13.1) .15
(85%–100%) 99% (95%–100%) .53
1 (101–169) 128 (102–176) .98
7 (27–45)y 30 (21–41)z .56
9 (25–32) 28 (25–32) .72
6 (11%) 6 (12%) .92
7 (13%) 7 (14%) .91
6 (11%) 4 (8%) >.99
.19
5 (9%) 3 (6%)
2 (78%) 46 (90%)
7 (13%) 2 (4%)
0 (37%) 22 (43%) .52
5 (9%) 2 (4%) .44
5 (51–90)
7 (166–230)
culation. *Estimated glomerular filtration rate calculated by the Schwartz formula as
.55 in children 1 to 13 years old, and k is 0.65 in boys at least 13 years old and 0.55 in
creatinine above the reference level corrected for age. yN ¼ 8. zN ¼ 9. xN ¼ 50.
rdiovascular Surgery c Volume 143, Number 3 579
TABLE 2. Postoperative outcome
RIPC Control P value
No. 54 51
Renal end points
Acute kidney injury* (no.) 27 (50%) 30 (59%) .36
Risk 15 (28%) 20 (39%)
Injury 6 (11%) 7 (14%)
Failure 6 (11%) 3 (6%)
Loss 0 (0%) 0 (0%)
End-stage 0 (0%) 0 (0%) .48
Dialysis (no.) 7 (13%) 5 (10%) .61
Secondary end points
Low blood pressurey (no.) 16 (30%) 12 (24%) .48
Highest inotropic score
(median and IQR)
4 (0–8) 4 (0–9) .71
Reoperation during
hospital stay (no.)
1 (2%) 2 (4%) .61
Intensive care unit stay
(d, median and IQR)
2.5 (1.0–8.0) 3.0 (1.0–4.0) .91
Hospital stay (d, median
and IQR)
9 (6–18) 8 (7–15) .73
In-hospital death (no.) 1 (2%) 2 (4%) .61
RIPC, Remote ischemic preconditioning; IQR, interquartile range. *Acute kidney in-
jury was defined as fulfilling at least 1 of the RIFLE criteria: R, risk, plasma creatinine
times 1.5 or urinary output less than 0.5 mL/(kg $ h) for 6 hours; I, injury, plasma cre-
atinine times 2 or urinary output less than 0.5 mL/(kg $ h) for 12 hours; F, failure,
plasma creatinine times 3 or plasma creatinine at least 350 mmoL/L in the setting
of an acute increase of at least 44 mmoL/L or urinary output less than 0.3 mL/(kg $
h) for 24 hours or anuria for 12 hours; L, loss, need for dialysis for longer than 4
weeks; E, end-stage, need for dialysis for longer than 3 months. yLow blood pressure
was defined as incidence of low blood pressure (below the age-reference level).
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Dof a combination of creatinine increase and associated oli-
guria. There was no difference in frequency of the type of
AKI between the RIPC and control group (P> .2). After
stratification of AKI according to the RIFLE criteria, the
tendency toward a lower incidence of AKI in the RIPC
group was limited to the mildest degrees of AKI, namely
the R and I criteria, with the strongest tendency in the R cri-
teria (Table 2). The mean difference between preoperative
eGFR and nadir postoperative eGFR in the RIPC group
was 32%  3.2%; the difference was 35%  2.5% in
the control group (P>.2). Dialysis was initiated in 7 pa-
tients in the RIPC group (13%) and in 5 patients in the con-
trol group (10%; P>.2; Table 2).
There were no differences in the levels of the renal bio-
markers with time between the RIPC group and the control
group. In the 2 groups combined, renal biomarkers, eGFR,
and urinary output all changed significantly with time
(Figure 2). Correcting urinary NGAL for urinary creatinine
did not change this conclusion.
A separate analysis of children older than 6 months
(RIPC, n ¼ 32; control, n ¼ 30) showed a difference in
the incidence of AKI (41% in RIPC group and 67% in con-
trol group; P¼ .04); however, this protective effect of RIPC
was not reflected in any other of the renal end points or in
any secondary end points (data not shown).580 The Journal of Thoracic and Cardiovascular SurgSecondary End Points
We found no difference in secondary end points between
the RIPC group and the control group (Table 2).DISCUSSION
In this study, we found no evidence of kidney protection
provided by RIPC in children undergoing operation for
complex congenital heart disease. We found a tendency to-
ward a lower incidence of AKI as defined by changes in
plasma creatinine and urinary output (the RIFLE criteria),
but this tendency was not supported by changes in more re-
cently developed renal biomarkers.
In 2007, Ali and colleagues13 showed a beneficial effect
of RIPC on kidney function, performed as crossclamping
of the iliac arteries, in patients undergoing surgery for ab-
dominal aortic aneurysm; however, a recent, larger study
by Rahman and associates14 in patients undergoing coro-
nary artery bypass grafting could not demonstrate any ef-
fect on kidney, heart, or lung function. Furthermore, Choi
and coworkers16 confirmed that RIPC could not protect
kidney function in adults after complex valvular heart sur-
gery. The reasons for these conflicting results could be re-
lated to the surgical procedure and thereby the degree of
ischemia–reperfusion injury or to differences in RIPC
techniques.
Cheung and associates6 and Zhou and coworkers8 found
a beneficial effect of RIPC on heart and lung function in
children undergoing operation for congenital heart disease.
In our study, we found no effect of RIPC on the incidence
of low blood pressure or IS. There are, however several
differences between the study by Cheung and associates6
and our own study that may explain this discrepancy.
In Cheung and associates’ study,6 most of the children
(84%) were in RACHS-1 category 2, compared with
only 13% in this study. ECC time was also shorter in
Cheung and associates’ study6 (mean ECC time, RIPC,
80 minutes, vs control, 88 minutes; compare with our study
in Table 1), as was stay in the ICU (mean ICU stay, RIPC,
2.3 days, vs control, 1.7 days; compare with our study in
Table 2). It therefore seems that morbidity in the study
population of Cheung and associates6 was lower than
that in our study population, and thus RIPC may be less
protective with greater complexity of heart disease. This
may also be true for the study by Zhou and coworkers,8
who only included ventricular septal defects (RACHS-1
category 2).
Another factor that may have influenced the outcome
after RIPC is the interval between RIPC and initiation of
ECC. RIPC was performed 5 to 10 minutes before initia-
tion of bypass in the study by Cheung and associates6 and
24 hours and 1 hour before surgery in the study by Zhou
and coworkers.8 According to the review by Kanoria and
colleagues,23 the first heart protective window of RIPCery c March 2012
FIGURE 2. Measurements of plasma and urinary renal biomarkers, estimated glomerular filtration rate (eGFR), and urinary output with time in the remote
ischemic preconditioning group and control group. Filled circles represent the remote ischemic preconditioning group; open circles represent the control
group. Nc, Number of patients in the control group; Nr, number of patients in the RIPC group; ICU, intensive care unit; POD, postoperative day; NGAL,
neutrophil gelatinase–associated lipocalin. Mean and SE are presented. There were no significant differences with time between the 2 groups in any of the
renal end point measurements. Asterisk indicates P<.05 for the difference from the preoperative measurement in the combined group.
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hours as a result of protein-independent and protein-
dependent phases. The median time between RIPC and
start of ECC in this study was 65 minutes, which repre-
sents the time between RIPC and the ischemic part of
the ischemia–reperfusion injury. The median time between
RIPC and completion of ECC was 187 minutes, which
represents the time between RIPC and the reperfusion
part of the ischemia–reperfusion injury (Table 1). This
means that even though timing of RIPC was different in
these 3 studies, the ischemic part of the ischemia–reperfu-
sion injury overall happened within the first window of
RIPC protection for all studies. Children with prolonged
preceding procedures or long ECC time, however, received
their reperfusion injury outside the first window of RIPC,
which may have reduced the effect of the first RIPC protec-
tive window in our study. Because the time between surgery
and start of ECC was not given in the study by Zhou and co-
workers,8 it is unknown whether their patients fully
benefited from the first protective window.The Journal of Thoracic and CaThe cuff inflation pressure could also have influenced the
effect of RIPC. Cheung and associates6 used a pressure of
15 mm Hg above systolic pressure, and Zhou and co-
workers8 inflated the cuff to 240 mm Hg. We used a cuff in-
flation pressure of 40mmHg above systolic pressure, which
is in between the 2 previous studies.
The lower incidence of AKI associated with RIPC in
the children older than 6 months may indicate that a cer-
tain maturation of the kidneys is needed for a response to
RIPC.
More subtle protection may have revealed itself in some
of the new renal markers. There was no evidence of any dif-
ference, however, in the release of either cystatin C or
NGAL. External factors known to influence the NGAL
level in plasma include inflammation (cystic fibrosis24 and
COPD25) and infections.18 There was, however, no differ-
ence in the incidence of infection between the 2 groups.
Only 1 patient was treated for asthma with glucocorticoid
inhalation; otherwise, the children did not have any comor-
bidities. The inflammatory response after cardiac surgery isrdiovascular Surgery c Volume 143, Number 3 581
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2 groups.
Imprecision in the measurement of NGAL could have ob-
scured a potential difference. We have previously shown
that hemolysis increases NGAL measurements in plasma.21
Patients with visible hemolysis and hematuria were equally
distributed between the RIPC and the control group. Ex-
cluding these patients from the analysis did not reveal any
beneficial effect of RIPC on plasma or urinary NGAL
(data not shown). The mechanisms of ischemia–reperfusion
injury and protection afforded by RIPC differ among or-
gans, and the kidneys may have weaker protective re-
sponses than organs (such as the heart, lungs, and brain)
that appear to receive clinically relevant protection from
RIPC. Further mechanistic studies of renal ischemia–reper-
fusion injury are merited to guide clinical trials geared to-
ward optimizing protective effects of pharmacologic or
ischemic preconditioning. Referral for operation was popu-
lation based, and the results therefore can be generalized to
most surgical procedures for complex congenital heart
disease.
Limitations
The study is undersized to detect less than a 30% reduc-
tion in AKI. The observed reduction in AKI of approxi-
mately 10% would have required 480 children in each
group to show statistically significance. The relative low
frequency of high RACHS-1 scores among our patients
might have reduced the overall occurrence of AKI; how-
ever, AKI did develop in 59% of patients in the control
group, which is in accordance with the assumption that
we made in the power calculation.
Although we used more than 1 renal biomarker, the end
points for renal function used in this study may still have
been too insensitive and unspecific.
AKI developed during the first 24 hours, and renal
function improved after this time. Within the first 24
hours, the number of missing values did not exceed
5%, and dropouts were only an issue after the second
postoperative day. To compensate for missing data, we in-
creased the total number of children above the estimated
power calculation. We therefore consider the incomplete
data set unlikely to have changed the overall findings in
this study.
The optimal measure of renal function could be ethylene-
diaminetetraacetic acid clearance; however, performance of
this test is complicated by the invasive nature of the
technique.
The vast majority of the children were anesthetized with
sevoflurane, equally distributed between the RIPC group
and the control group. A preconditioning effect of sevoflur-
ane thus may have provided a renal protection that could not
be augmented by RIPC. The children in the study by
Cheung and associates6 were all anesthetized with582 The Journal of Thoracic and Cardiovascular Surgsevoflurane, however, and those investigators found heart
and lung RIPC protective effects.CONCLUSIONS
In this randomized study of RIPC in children during sur-
gery for complex congenital heart disease, we could not
demonstrate any beneficial effect on the postoperative oc-
currence of AKI. Furthermore, we found no evidence that
RIPC affected the plasma level of cystatin C or the release
of NGAL in plasma and urine.
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C
H
DRemote ischemic preconditioning for renal protection in children
undergoing surgery for complex congenital heart disease: What do we
know now and where do we go next?James S. Tweddell, MDIn 1986, Murry, Jennings, and Reimer1 found in a canine
model that brief periods of occlusion of the circumflex cor-
onary artery preceding a 40-minute period of ischemia fol-
lowed by reperfusion could reduce the size of the resultant
infarct. This phenomenon was termed ‘‘preconditioning.’’
Subsequent work found that this protective effect could be
elicited by creating brief ischemic episodes in tissue beds
remote from the organ to be rendered ischemic. The protec-
tive effect of these remote ischemic events could even occur
simultaneous to (percondititioning) or after (postcondition-
ing) the ischemic insult.2
Remote ischemic preconditioning (RIPC) has been
shown in 2 randomized controlled trials to improve cardiac
and pulmonary function in children undergoing cardiac
surgery.3,4 Other investigators have shown that RIPC hasa favorable impact on renal function.5 RIPC is an attractive
and exciting area of study. The technique unmasks an innate
ability to ameliorate ischemia–reperfusion (I-R) injury. No
drugs are required and the technique of RIPC appears to
have little or no potential for morbidity.
In the current study, the group from Aarhus University
Hospital, Skejby, Denmark, performed an extremely
well-structured randomized double-blind placebo-
controlled trial of RIPC to assess the potential for protec-
tion of renal function among children undergoing cardiac
surgery.6 On the basis of their initial hypothesis, they
found that RIPC provided no protection of renal function
in children operated on for complex congenital heart dis-
ease. Despite the ultimate clinical study design, perhaps
the optimal technique of RIPC for renal protection in
this patient population has not been identified. Do we
know enough about the proper timing, duration, type,
and quantity of vascular bed to be rendered temporarily
ischemic to merit a randomized trial? A subanalysis did
identify a benefit among patients greater than 6 months
of age, suggesting that there is an age-dependent response
to RIPC. Clearly, younger patients are at increased risk of
I-R injury and multiorgan dysfunction after operations us-
ing cardiopulmonary bypass. Any protective impact of
RIPC may have been overwhelmed by increased I-R injury
seen in young infants.rdiovascular Surgery c Volume 143, Number 3 583
